554 related articles for article (PubMed ID: 23891770)
1. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Özcetin A; Aigner A; Bakowsky U
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):711-5. PubMed ID: 23891770
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
3. The gelatin sponge-chorioallantoic membrane assay.
Ribatti D; Nico B; Vacca A; Presta M
Nat Protoc; 2006; 1(1):85-91. PubMed ID: 17406216
[TBL] [Abstract][Full Text] [Related]
4. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
5. Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma.
Zheng L; He X; Ma W; Dai B; Zhan Y; Zhang Y
Biomed Pharmacother; 2012 Oct; 66(7):499-505. PubMed ID: 22854322
[TBL] [Abstract][Full Text] [Related]
6. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
Nakagawa H; Takiguchi T; Nakamura M; Furuyama A; Koyanagi S; Aramaki H; Higuchi S; Ohdo S
Biochem Pharmacol; 2006 Nov; 72(10):1237-45. PubMed ID: 16973134
[TBL] [Abstract][Full Text] [Related]
7. New role of lupeol in reticence of angiogenesis, the cellular parameter of neoplastic progression in tumorigenesis models through altered gene expression.
Vijay Avin BR; Prabhu T; Ramesh CK; Vigneshwaran V; Riaz M; Jayashree K; Prabhakar BT
Biochem Biophys Res Commun; 2014 May; 448(2):139-44. PubMed ID: 24780400
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
10. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
11. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
12. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
13. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
14. Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
Zhao J; Lin W; Zhuang Q; Zhong X; Cao Z; Hong Z; Peng J
Integr Cancer Ther; 2014 Nov; 13(6):520-8. PubMed ID: 25148840
[TBL] [Abstract][Full Text] [Related]
15. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
16. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative.
Yi EY; Jeong EJ; Song HS; Lee MS; Kang DW; Joo JH; Kwon HS; Lee SH; Park SK; Chung SG; Cho EH; Kim YJ
Int J Oncol; 2004 Aug; 25(2):365-72. PubMed ID: 15254733
[TBL] [Abstract][Full Text] [Related]
18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic preparation of κ-carrageenan oligosaccharides and their anti-angiogenic activity.
Yao Z; Wu H; Zhang S; Du Y
Carbohydr Polym; 2014 Jan; 101():359-67. PubMed ID: 24299784
[TBL] [Abstract][Full Text] [Related]
20. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
